TopiVert is a private, clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinase Inhibitors as novel, topical, non-systemic medicines for the treatment of chronic inflammatory diseases of the gastrointestinal tract and the eye.
Total raised: $27.9M
Founded date: 2011
Investors 1
| Date | Name | Website |
| - | NeoMed Man... | neomed.net... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.01.2014 | - | $27.9M | NeoMed Man... |
Mentions in press and media 1
| Date | Title | Description |
| 06.01.2014 | NeoMed invests in TopiVert in a £17 million new funding round | TopiVert Limited, a drug discovery and development company dedicated to improving patient care in inflammatory diseases of the gut and the eye, has announced that it has closed a £17 million financing round. New investors NeoMed Management... |